Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ACNE
MCID: ACN011
MIFTS: 55

Acne (ACNE)

Categories: Endocrine diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Acne

About this section

MalaCards integrated aliases for Acne:

Name: Acne 12 73 29 42 15 62 17 32
Acne Vulgaris 12 73 54 44 15 32
Acne Varioliformis 12 32
Frontalis Acne 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:6543
ICD9CM 34 706.0
MeSH 44 D000152
SNOMED-CT 67 11381005 201210008
UMLS 70 C0152249 C0702166
Sources

Summaries for Acne

About this section
MedlinePlus : 42 Acne is a common skin disease that causes pimples. Pimples form when hair follicles under your skin clog up. Most pimples form on the face, neck, back, chest, and shoulders. Anyone can get acne, but it is common in teenagers and young adults. It is not serious, but it can cause scars. No one knows exactly what causes acne. Hormone changes, such as those during the teenage years and pregnancy, probably play a role. There are many myths about what causes acne. Chocolate and greasy foods are often blamed, but there is little evidence that foods have much effect on acne in most people. Another common myth is that dirty skin causes acne; however, blackheads and pimples are not caused by dirt. Stress doesn't cause acne, but stress can make it worse. If you have acne Clean your skin gently Try not to touch your skin Avoid the sun Treatments for acne include medicines and creams. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Acne, also known as acne vulgaris, is related to hidradenitis suppurativa and hidradenitis. An important gene associated with Acne is NCSTN (Nicastrin), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Lymecycline and Erythromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and thyroid, and related phenotypes are Increased shRNA abundance and cardiovascular system

Disease Ontology : 12 A sebaceous gland disease characterized by areas of blackheads, whiteheads, pimples, greasy skin, and possibly scarring.

PubMed Health : 62 About acne: Most teenagers will have pimples at some point. Some only have a few small pimples that soon go away again. Others develop more severe, persistent and clearly visible acne. This can be very distressing, particularly in puberty. But there are a number of things that can be done about acne, although patience is needed. This information is about acne in teenagers and young adults, known as “common acne or acne vulgaris.

Wikipedia : 73 Acne, also known as acne vulgaris, is a long-term skin condition that occurs when dead skin cells and... more...

Sources

Related Diseases for Acne

About this section

Diseases in the Acne family:

Acne, Adult

Diseases related to Acne via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 666)
# Related Disease Score Top Affiliating Genes
1 hidradenitis suppurativa 32.9 PSENEN PSEN1 NCSTN IL1A
2 hidradenitis 31.8 PSENEN PSEN1 NCSTN IL1A
3 pustulosis of palm and sole 31.4 PSTPIP1 IL1RN CXCL8
4 bone inflammation disease 31.4 TLR2 IL1RN IL1A CXCL8
5 behcet syndrome 31.4 TLR2 PSTPIP1 MPO IL1RN IL1A CXCL8
6 skin disease 31.3 TLR2 MPO IL1A FLG FGFR2 DEFB4A
7 osteomyelitis 31.1 TLR2 IL1RN IL1A CXCL8
8 dermatitis 30.9 TLR2 IL1A FLG DEFB4A CXCL8
9 synovitis 30.9 IL1RN IL1A CXCL8
10 seborrheic dermatitis 30.9 SHBG FLG DEFB4A
11 psoriasis 30.9 TLR2 IL1A FLG DEFB4A CXCL8 ALOX5
12 dermatitis, atopic 30.7 TLR2 IL1A FLG DEFB4A CXCL8
13 irritant dermatitis 30.7 IL1A FLG CXCL8
14 arthritis 30.7 TLR2 PSTPIP1 IL1RN IL1A CXCL8
15 contact dermatitis 30.6 TLR2 IL1A FLG DEFB4A CXCL8
16 keratitis, hereditary 30.6 TLR2 IL1A CXCL8
17 crohn's disease 30.5 TLR2 MPO IL1A DEFB4A CXCL8
18 lichen planus 30.3 FLG DEFB4A CXCL8
19 candidiasis 30.3 TLR2 DEFB4A DEFB1 CXCL8
20 familial mediterranean fever 30.3 TLR2 PSTPIP1 IL1RN IL1A CXCL8
21 chlamydia 30.3 TLR2 IL1A CXCL8
22 brucellosis 30.3 MPO IL1RN CXCL8
23 vaginitis 30.3 TLR2 IL1A DEFB4A CXCL8
24 allergic contact dermatitis 30.2 IL1RN FLG DEFB4A CXCL8
25 proteasome-associated autoinflammatory syndrome 1 30.2 TLR2 MPO IL1RN IL1A CXCL8 ALOX5
26 sebaceous gland disease 30.2 TLR2 SHBG PSTPIP1 PSENEN NCSTN IL1A
27 alopecia areata 30.2 IL1RN IL1A FLG
28 endocarditis 30.2 TLR2 IL1A CXCL8
29 reactive arthritis 30.2 TLR2 MPO CXCL8
30 colitis 30.2 TLR2 MPO IL1RN DEFB4A CXCL8
31 mycobacterium chelonae 30.1 TLR2 CXCL8
32 anal canal squamous cell carcinoma 30.1 PSENEN NCSTN
33 food allergy 30.0 TLR2 FLG CXCL8
34 aseptic meningitis 30.0 IL1RN IL1A CXCL8
35 urethritis 30.0 TLR2 DEFB4A CXCL8
36 pneumonia 29.9 TLR2 MPO DEFB4A CXCL8
37 neutrophilic dermatosis, acute febrile 29.8 PSTPIP1 MPO IL1RN CXCL8
38 otitis media 29.8 TLR2 MPO IL1A CXCL8
39 vulvovaginal candidiasis 29.8 TLR2 IL1RN DEFB4A DEFB1
40 bacterial infectious disease 29.8 TLR2 IL1RN IL1A DEFB4A DEFB1 CXCL8
41 septic arthritis 29.8 TLR2 MMP2 DEFB4A CXCL8
42 bronchiectasis 29.7 TLR2 MPO CXCL8
43 gastritis 29.6 IL1RN DEFB4A DEFB1 CXCL8
44 type 2 diabetes mellitus 29.5 SHBG RBP4 MPO MMP2 IL1RN CYP1A1
45 inflammatory bowel disease 29.5 TLR2 PSTPIP1 MPO MMP2 IL1RN IL1A
46 peptic ulcer disease 29.4 IL1RN DEFB4A DEFB1 CXCL8
47 disease of mental health 29.4 TLR2 SHBG PSENEN PSEN1 NCSTN MPO
48 cystic fibrosis 29.3 TLR2 MPO IL1A DEFB4A DEFB1 CXCL8
49 diabetes mellitus 29.3 TLR2 SHBG RBP4 MPO MMP2 IL1RN
50 tonsillitis 29.2 TLR2 MPO IL1A DEFB4A DEFB1 CXCL8

Graphical network of the top 20 diseases related to Acne:



Diseases related to Acne
Sources

Symptoms & Phenotypes for Acne

About this section

GenomeRNAi Phenotypes related to Acne according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.02 CYP1A1 DEFB1 FGFR2 G6PD IL1RN

MGI Mouse Phenotypes related to Acne:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.93 ALOX5 FGFR2 G6PD GATA6 IL1A IL1RN
2 hematopoietic system MP:0005397 9.77 ALOX5 CYP1A1 FGFR2 G6PD GATA6 IL1A
3 immune system MP:0005387 9.36 ALOX5 CYP1A1 FGFR2 IL1A IL1RN MMP2
Sources

Drugs & Therapeutics for Acne

About this section

PubMed Health treatment related to Acne: 62

People with acne often try out different things to improve the appearance of their skin . There are a lot of different recommendations when it comes to acne, involving things like facial toners, sunlight and specific diets. There are also a number of medications for acne . Some are applied to the skin , some are swallowed. Because you can buy them without a prescription, many of the products are heavily marketed. But advert ising campaigns often create unrealistic expectations. Some treatment approaches and medications have been proven to effectively reduce acne, while others have not. Unfortunately there are only a few good-quality studies comparing the various treatments with each other. So it is not possible to tell whether certain products are more effective than others. Most products have to be used for a long time before there is a noticeable improvement. And some have strong side effects.

Drugs for Acne (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
2
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
3
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
4
Adapalene Approved Phase 4 106685-40-9 60164
5
Azelaic acid Approved Phase 4 123-99-9 2266
6
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
7
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
8
Dapsone Approved, Investigational Phase 4 80-08-0 2955
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
14
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
15
Sarecycline Approved, Investigational Phase 4 1035654-66-0
16
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
17
Coal tar Approved Phase 4 8007-45-2
18
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
19
tannic acid Approved Phase 4 1401-55-4
20
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
21
Desogestrel Approved Phase 4 54024-22-5 40973
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
24
Prilocaine Approved Phase 4 721-50-6 4906
25
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
26
Ethanol Approved Phase 4 64-17-5 702
27
Chamomile Approved, Experimental, Investigational Phase 4
28
Caffeine Approved Phase 4 58-08-2 2519
29
Trifarotene Approved, Investigational Phase 4 895542-09-3
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
33
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
34
Sage Approved Phase 4
35
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
36
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
39
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
40
Nadifloxacin Investigational Phase 4 124858-35-1
41
Resveratrol Investigational Phase 4 501-36-0 445154
42
Rosemary Experimental Phase 4
43 Gastrointestinal Agents Phase 4
44 Erythromycin Estolate Phase 4
45 Erythromycin stearate Phase 4
46 Erythromycin Ethylsuccinate Phase 4
47 Adapalene, Benzoyl Peroxide Drug Combination Phase 4
48 Androgen Antagonists Phase 4
49 Clindamycin phosphate Phase 4
50 Clindamycin palmitate Phase 4

Interventional clinical trials:

(show top 50) (show all 630)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris. Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
2 Multicentric, Parallel, Randomized, Double Blind Study Under Dermatological Control to Evaluate the Anti-acne Efficacy of a Dermo-cosmetic Product (Fla 688977 33) Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer (Hydréane légère, Cosmétique Active International) During a 12-week Application Period in Male and Female Subjects Presenting With Mild to Moderate Acne Unknown status NCT03832647 Phase 4 Salicylic Acid
3 Vitamin D and Its Topical Analogues: A Possible Role in the Pathogenesis and Treatment of Acne Vulgaris Unknown status NCT03866447 Phase 4 Vitamin D analog;Adapalene
4 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
5 A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment of Facial Acne Vulgaris Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
6 A Randomized, Placebo-controlled, Evaluator-blinded, Study to Assess the Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Patients With Inflammatory Facial Acne Unknown status NCT03883269 Phase 4 Erythromycin 4% topical gel formulation;Clindamycin 1% topical lotion formulation;70% topical ethanol solution
7 Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks Unknown status NCT00988026 Phase 4 Minocycline vs Lymecycline
8 Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel) Unknown status NCT00237978 Phase 4 Adapalen
9 Efficacy & Safety of Clindamycin Phosphase 1.2% and Tretinoin 0.025% Gel vs. Vehicle for the Treatment of Acne and Acne-Induced Post Inflammatory Hyperpigmentation in Patients With Skin of Color Unknown status NCT01111994 Phase 4 Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
10 Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females Completed NCT01387048 Phase 4 skinoren;differin;skinoren
11 The Effects of Oral Isotretinoin in Women With Acne and Polycystic Ovary Syndrome Completed NCT02855138 Phase 4 oral isotretinoin
12 Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
13 A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morning For the Treatment of Facial Acne Vulgaris Completed NCT00907257 Phase 4 benzoyl peroxide wash;Tretinoin gel
14 Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects Completed NCT02735421 Phase 4 Adapalene 0.3% / BPO 2.5% gel;Vehicle gel
15 Pilot Study of Tolerability and Effectivity Following Application of Two Combination Topical Acne Products Clindamycin 1% and 0.025% Tretinoin Gel (Acnatac® Gel), Adapalen 0,1% and Benzoyl Peroxide 2,5% Gel (Epiduo® Gel) Completed NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
16 An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model Completed NCT00714714 Phase 4 Adapalene Gel;Tretinoin Gel
17 De Novo Lipogenesis of Sebaceous Glands in Acne Completed NCT02620813 Phase 4 Tretinoin;Isotretinoin
18 An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
19 An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model Completed NCT00952523 Phase 4 Tretinoin Facial Gel;Adapalene/Benzoyl Peroxide Facial Gel
20 Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use Completed NCT00939133 Phase 4 tretinoin microsphere 0.04% gel;vehicle gel
21 Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia: A Multicenter Clinical Trial Completed NCT03626298 Phase 4 Adapalene;Nicotinamide, ABA and Zinc PCA;Placebos
22 Acne Free vs. Proactiv for the Treatment of Moderately Severe Acne Vulgaris Completed NCT00913185 Phase 4 Acne Free, Proactiv
23 Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne Completed NCT00658112 Phase 4 Benzoyl Peroxide
24 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris Completed NCT00841776 Phase 4 Duac;Ziana gel
25 Anti P. Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel in the Treatment of Subjects With Acne Vulgaris Completed NCT01188538 Phase 4 Epiduo gel;BPO
26 ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%. Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
27 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Completed NCT02944461 Phase 4 Dapsone 7.5 % gel
28 Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects Completed NCT02899000 Phase 4 Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel;Oral doxycycline hyclate
29 Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
30 Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazorac .1% Gel or Vehicle Gel Completed NCT00145106 Phase 4 Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
31 Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
32 Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris Completed NCT01047189 Phase 4 clindamycin phosphate 1.2% and tretinoin 0.025%;clindamycin 1% gel;tretinoin 0.025% cream
33 Efficacy and Safety of Finacea in the Treatment of Post-Inflammatory Hyperpigmentation and Acne Vulgaris Completed NCT01038869 Phase 4 Azelaic acid
34 An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris. Completed NCT00437151 Phase 4
35 Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac® Gel And Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris Completed NCT00160394 Phase 4 Duac® Gel / Differin® Gel
36 Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris Completed NCT01209949 Phase 4 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
37 Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Completed NCT01149330 Phase 4 Adapalene-BPO Gel
38 A Single-blind, Randomized, Comparative Split-face Study Evaluating the Tolerability of Clindamycin and Benzoyl Peroxide Gel to Benzoyl Peroxide/Adapalene Gel in the Treatment of Acne Vulgaris. Completed NCT00964223 Phase 4 Clindamycin and benzoyl peroxide gel (Duac® Topical Gel);benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
39 Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial Completed NCT02721173 Phase 4 Tazarotene 0.1% gel plus clindamycin 1% gel;Adapalene 0.1% gel plus clindamycin 1% gel
40 A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-Week Treatment Switched to Tazorac® Cream, 0.1% 6-Week Treatment in Patients With Acne Vulgaris Completed NCT00469755 Phase 4 Adapalene Gel, 0.1%;Tazarotene Cream, 0.1%;Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
41 Phase IV Clinical Study Of Clindamycin Phosphate Topical Gel In The Treatment Of Acne Vulgaris Completed NCT00219570 Phase 4 clindamycin;nadifloxacin
42 A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris Completed NCT01138735 Phase 4 adapalene/benzoyl peroxide;Topical Gel Vehicle
43 An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Completed NCT02959970 Phase 4 dapsone gel
44 A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris Completed NCT01016977 Phase 4 Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene;clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
45 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
46 Single-blind, Multicenter, Parallel, Comparative, Randomized, Phase 4 Clinical Trial for the Evaluation of the Quality of Life, Efficacy and Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris. Completed NCT00807014 Phase 4 Duac Gel;Differin gel
47 A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris Completed NCT00660985 Phase 4 Adapalene;Adapalene
48 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Doryx Tablets Compared to Doxycycline Hyclate in the Treatment of Acne Vulgaris. Completed NCT00635609 Phase 4 Doxycycline hyclate (Doryx);Doxycycline hyclate
49 A Multi-centre, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
50 Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel

Search NIH Clinical Center for Acne

Inferred drug relations via UMLS 70 / NDF-RT 51 :


adapalene
azelaic acid
Benzoyl Peroxide
CLINDAMYCIN PHOSPHATE PWDR
Colloid sulfur
Desogestrel
ERYTHROMYCIN PWDR
Hexachlorophene
Isotretinoin
MECLOCYLINE SULFOSALICYLATE
Norethindrone
norethindrone acetate
resorcinol
RESORCINOL PWDR
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Tretinoin
TRETINOIN PWDR

Cochrane evidence based reviews: acne vulgaris

Sources

Genetic Tests for Acne

About this section

Genetic tests related to Acne:

# Genetic test Affiliating Genes
1 Acne 29
Sources

Anatomical Context for Acne

About this section

MalaCards organs/tissues related to Acne:

40
Skin, Ovary, Thyroid, Breast, Neutrophil, Pituitary, Lung
Sources

Publications for Acne

About this section

Articles related to Acne:

(show top 50) (show all 16060)
# Title Authors PMID Year
1
Effectiveness of CO2 laser therapy in treating acne depressed scar: A protocol of systematic review. 42 61
33545938 2021
2
Association between Satisfaction with Life and Personality Types A and D in Young Women with Acne Vulgaris. 42 61
33212977 2020
3
The Challenge of Nanovesicles for Selective Topical Delivery for Acne Treatment: Enhancing Absorption Whilst Avoiding Toxicity. 42 61
33239876 2020
4
[Modern aspects of acne pathogenesis]. 61 54
20482694 2010
5
Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. 54 61
18704103 2009
6
TLR2 and TLR4 polymorphisms are not associated with acne vulgaris. 61 54
17033191 2006
7
Defensins and acne. 54 61
14568392 2003
8
Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. 54 61
11710922 2001
9
Peroxisomes in dermatology. Part II. 61 54
11907843 2001
10
Peroxisomes in dermatology. Part I. 54 61
11685671 2001
11
Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. 54 61
9557222 1998
12
Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. 61 54
9068725 1997
13
Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. 54 61
8689881 1996
14
Androgen levels in women using a single implant of nomegestrol acetate. 54 61
8631188 1996
15
Inflammatory levels of interleukin 1 alpha are present in the majority of open comedones in acne vulgaris. 61 54
1830734 1991
16
The relevance of nanotechnology, hepato-protective agents in reducing the toxicity and augmenting the bioavailability of isotretinoin. 61
33355019 2021
17
Dapsone-induced hepatic complications: it's time to think beyond methemoglobinemia. 61
31631707 2021
18
Stem and progenitor cells in sebaceous gland development, homeostasis and pathologies. 61
33599012 2021
19
High-velocity pneumatic injection of non-crosslinked hyaluronic acid for skin regeneration and scar remodeling: A retrospective analysis of 115 patients. 61
33580573 2021
20
Comparison of patients' diagnoses in a dermatology outpatient clinic during the COVID-19 pandemic period and pre-pandemic period. 61
33332694 2021
21
Clinical characteristics of pediatric synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: the first Chinese case series from a single center. 61
32929648 2021
22
No association between atopic dermatitis and acne vulgaris in the general population. 61
33222279 2021
23
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
24
Fibromyalgia in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: prevalence and screening. 61
32949312 2021
25
[Neuroendorine paraneoplastic syndromes]. 61
33661337 2021
26
Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. 61
33030217 2021
27
Psychodermatology of acne: Psychological aspects and effects of acne vulgaris. 61
33031607 2021
28
Acne keloidalis nuchae and thyroid diseases: a population-based cohort study. 61
33301179 2021
29
Serum Sp17 Autoantibody Serves as a Potential Specific Biomarker in Patients with SAPHO Syndrome. 61
33392854 2021
30
Rare cases of PAMI syndrome in both father and son with the same missense mutation in PSTPIP1 gene and literature review. 61
33458872 2021
31
Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. 61
33547675 2021
32
Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. 61
33007126 2021
33
Preparing the hair follicle canal for hair shaft emergence. 61
33025661 2021
34
Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015. 61
33683646 2021
35
Isotretinoin plus 420 nm intense pulsed light versus isotretinoin alone for the treatment of acne vulgaris: a randomized, controlled study of efficacy, safety, and patient satisfaction in Chinese subjects. 61
32728814 2021
36
TikTok, teens, and isotretinoin: Recommendations for identifying trending acne-related content on the world's most popular social media platform. 61
33811769 2021
37
Acne in the first three decades of life: An update of a disorder with profound implications for all decades of life. 61
33041056 2021
38
Efficacy of non-ablative fractional 1440-nm laser therapy for treatment of facial acne scars in patients with rosacea: a prospective, interventional study. 61
32719961 2021
39
Inferences in microbial structural signatures of acne microbiome and mycobiome. 61
33565055 2021
40
Innovative method of intralesional drug delivery in nodulocystic acne. 61
31585143 2021
41
Combined Treatment of Rolling Acne Scars in Ethnic Skin Using Extensive Subcision, Trichloracetic Acid Peel, and Fractional Ablative Erbium Laser. 61
33795570 2021
42
Comparative analysis of prescribing patterns of tetracycline class antibiotics and spironolactone between advanced practice providers and physicians in the treatment of acne vulgaris. 61
32561369 2021
43
A strategic review on the involvement of receptors, transcription factors and hormones in acne pathogenesis. 61
32787477 2021
44
Isotretinoin in the management of acne vulgaris: practical prescribing. 61
32860434 2021
45
Contrasting the efficacy of pulsed dye laser and photodynamic methylene blue nanoemulgel therapy in treating acne vulgaris. 61
32449013 2021
46
Dermal delivery and follicular targeting of adapalene using PAMAM dendrimers. 61
33666878 2021
47
Pachydermoperiostosis Presenting With Vision Loss Secondary to Severe Phlyctenular Keratoconjunctivitis. 61
33758137 2021
48
Placental weight Z-score and pubertal timing: A population-based cohort study. 61
33016465 2021
49
[Pre- and post-interventional skin care for laser and peel treatments]. 61
33763749 2021
50
Cutibacterium acnes: the Urgent Need To Identify Diagnosis Markers. 61
33468579 2021
Sources

Variations for Acne

About this section
Sources

Expression for Acne

About this section
Search GEO for disease gene expression data for Acne.
Sources

Pathways for Acne

About this section

Pathways related to Acne according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.56 TLR2 PSTPIP1 PSEN1 NCSTN MPO MMP2
2
NF-kappaB Signaling 4
12.23 TLR2 MPO IL1RN GATA6 ALOX5
3
Development NOTCH1-mediated pathway for NF-KB activity modulation 23
Show member pathways
 11.99 PSENEN PSEN1 NCSTN IL1A
4
AGE-RAGE signaling pathway in diabetic complications 36
11.7 MMP2 IL1A CXCL8
5
Rheumatoid arthritis 36
11.65 TLR2 IL1A CXCL8
6
Interleukin-4 and 13 signaling 65
11.61 MMP2 IL1A CXCL8 ALOX5
7
p75(NTR)-mediated signaling 1
Show member pathways
 11.49 PSENEN PSEN1 NCSTN
8
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 MMP2 IL1A CXCL8
9
Interleukin-10 signaling 65
11.3 IL1RN IL1A CXCL8
10
Presenilin action in Notch and Wnt signaling 1
11.21 PSENEN PSEN1 NCSTN
11
A-beta Pathways: Plaque Formation and APP Metabolism 64
10.62 PSENEN PSEN1 NCSTN MMP2
12
Syndecan-3-mediated signaling events 1
10.15 PSENEN PSEN1 NCSTN CXCL8
13
Notch Pathway 69
10.1 PSENEN PSEN1
Sources

GO Terms for Acne

About this section

Cellular components related to Acne according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 RBP4 MPO MMP2 IL1RN IL1A DEFB4A
2 extracellular region GO:0005576 9.7 SHBG RBP4 MPO MMP2 IL1RN IL1A
3 gamma-secretase complex GO:0070765 8.8 PSENEN PSEN1 NCSTN

Biological processes related to Acne according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 10 TLR2 PSEN1 NCSTN MPO ALOX5
2 immune response GO:0006955 9.99 TLR2 IL1RN IL1A DEFB4A DEFB1 CXCL8
3 cytokine-mediated signaling pathway GO:0019221 9.95 MMP2 IL1RN IL1A CXCL8 ALOX5
4 response to lipopolysaccharide GO:0032496 9.88 TLR2 MPO FGFR2 CYP1A1
5 defense response GO:0006952 9.87 MPO DEFB4A DEFB1 CXCL8
6 cellular protein metabolic process GO:0044267 9.85 PSENEN PSEN1 NCSTN MMP2 GATA6
7 inflammatory response GO:0006954 9.85 TLR2 PSTPIP1 IL1RN IL1A CXCL8 ALOX5
8 defense response to Gram-positive bacterium GO:0050830 9.81 TLR2 DEFB4A DEFB1
9 positive regulation of tumor necrosis factor production GO:0032760 9.79 TLR2 PSEN1 IL1A
10 protein processing GO:0016485 9.77 PSENEN PSEN1 NCSTN
11 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.77 DEFB4A DEFB1 CXCL8
12 skeletal system morphogenesis GO:0048705 9.73 PSEN1 MMP2 FGFR2
13 ephrin receptor signaling pathway GO:0048013 9.71 PSENEN PSEN1 NCSTN MMP2
14 positive regulation of catalytic activity GO:0043085 9.7 PSENEN PSEN1 NCSTN
15 membrane protein ectodomain proteolysis GO:0006509 9.67 PSENEN PSEN1 NCSTN
16 response to food GO:0032094 9.65 MPO G6PD CYP1A1
17 amyloid-beta metabolic process GO:0050435 9.63 PSEN1 NCSTN
18 positive regulation of endopeptidase activity GO:0010950 9.63 PSENEN NCSTN
19 epithelial cell proliferation GO:0050673 9.62 PSEN1 NCSTN
20 response to molecule of bacterial origin GO:0002237 9.61 TLR2 CXCL8
21 membrane protein intracellular domain proteolysis GO:0031293 9.61 PSENEN PSEN1 NCSTN
22 embryonic organ morphogenesis GO:0048562 9.58 RBP4 FGFR2
23 response to iron(III) ion GO:0010041 9.54 G6PD CYP1A1
24 amyloid precursor protein catabolic process GO:0042987 9.5 PSENEN PSEN1 NCSTN
25 amyloid precursor protein metabolic process GO:0042982 9.43 PSENEN PSEN1 NCSTN
26 amyloid-beta formation GO:0034205 9.33 PSENEN PSEN1 NCSTN
27 Notch receptor processing GO:0007220 9.13 PSENEN PSEN1 NCSTN
28 Notch receptor processing, ligand-dependent GO:0035333 8.8 PSENEN PSEN1 NCSTN

Molecular functions related to Acne according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 TLR2 SHBG RBP4 PSTPIP1 PSENEN PSEN1
2 endopeptidase activity GO:0004175 9.43 PSEN1 NCSTN MMP2
3 interleukin-1 receptor binding GO:0005149 9.32 IL1RN IL1A
4 growth factor receptor binding GO:0070851 9.16 PSEN1 NCSTN
5 CCR6 chemokine receptor binding GO:0031731 8.96 DEFB4A DEFB1
Sources

Sources for Acne

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....